Apyx Medical Corporation — Form 8-K
Filed: September 29, 2026. The filing reports an event on that date. It does not provide quarterly or annual financial results.
Business context and event
Apyx Medical announced publication in Plastic and Reconstructive Surgery — Global Open of clinical data from a prospective study evaluating biological markers of skin quality after use of its Renuvion helium plasma radiofrequency technology. The press release is identified as Exhibit 99.1, but its contents are not included in the provided filing text.
Financial information
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparison with a prior period.
Outlook, risks, and unusual items
No financial guidance, outlook, risks, contingencies, or quantified study results are provided in the supplied text. The filing does not establish the study’s findings beyond describing its subject.
Facts to verify
- Review Exhibit 99.1 for the study’s results, design, sample size, and any stated limitations.
- Check the publication for details supporting the reported evaluation of Renuvion and skin-quality markers.
- Consult the company’s periodic reports for current financial performance and risk factors.